A case report published in Frontiers in Neuroscience documents a woman with advanced Alzheimer’s disease who showed significant improvements in brain function after taking psilocybin-containing mushrooms. The Japanese American woman, whose name was not disclosed, had lived with Alzheimer’s disease and experienced severe functional decline for roughly five years.
The patient presented with advanced dementia, very limited speech or communication, severe cognitive impairment, urinary incontinence, and reduced mobility. She received two doses of psilocybin: a 5-gram oral dose, followed by a 3-gram dose one month later. After the first dose, she experienced profuse sweating and hyperthermia, followed by a prolonged sleep-like state. Approximately 19 hours later, she “spontaneously initiated autobiographical conversation lasting several hours,” the researchers documented. Over the following days and weeks, the woman regained urinary continence, was able to walk independently, dressed herself, and engaged in spontaneous conversation while retrieving contextual memories and expressing emotions.
Following the second dose, improvements became more pronounced, with greater speech capabilities, more facial expressions and humor, increased walking agility, and continued continence. Beyond the heavy sweating, hyperthermia, and initial sleep-like state, she experienced no severe or persistent adverse effects. The reported benefits lasted for at least one month, though longer-term follow-up data was not provided.
Researchers emphasized critical limitations of the single-case study: there was no control group, standardized cognitive assessments, brain imaging biomarkers, or electrophysiological monitoring. The patient’s Alzheimer’s diagnosis was not confirmed with modern biomarkers, and other neurodegenerative conditions could not be completely ruled out. Researchers could not establish that psilocybin directly caused the improvements, as the patient may have experienced natural fluctuations. Oregon began licensing psilocybin service centers in 2023, while Colorado’s regulated natural medicine program became operational in 2025, and New Mexico enacted a Medical Psilocybin Act in 2025.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/woman-with-advanced-alzheimer-s-regained-speech-and-84305543